Study #COGACNS0332
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
MD Anderson Study Status
Not Accepting
Treatment Agent
Cisplatin, Cyclophosphamide, Filgrastim, Vincristine Sulfate, Carboplatin, Isotretinoin
Description
This phase III trial studies different chemotherapy and radiation therapy regimens to compare how well they work in treating young patients with newly diagnosed, previously untreated, high-risk medulloblastoma. Chemotherapy drugs, such as vincristine sulfate, cisplatin, cyclophosphamide, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Carboplatin may make tumor cells more sensitive to radiation therapy. It is not yet known which chemotherapy and radiation therapy regimen is more effective in treating brain tumors.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Anaplastic Medulloblastoma, Medulloblastoma
Study phase:
Phase III
Physician name:
Najat Daw Bitar
Department:
Pediatrics
For general questions about clinical trials:
1-844-515-1914
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.